Literature DB >> 25788136

Towards scale-up and regulatory shelf-stability testing of curcumin encapsulated polyester nanoparticles.

Charitra N Grama1, Vinod P Venkatpurwar, Dimitrios A Lamprou, M N V Ravi Kumar.   

Abstract

This study reports scale-up and shelf-stability of curcumin encapsulated poly(lactic acid-co-glycolic acid) (PLGA) nanoparticles. The curcumin encapsulated PLGA nanoparticles were prepared by emulsification solvent evaporation/diffusion, and large quantities were made by varying the homogenisation time (5, 15 and 30 min). The particle size decreased as the homogenisation duration increased from 5 to 30 min, and the particles were spherical as confirmed by atomic force microscopy. For the large-scale preparations, the mean particles size was found to be 288.7 ± 3.4 (polydispersity index 0.15 ± 0.01) with curcumin entrapment 52.5 ± 4.3 %, which were comparable to the lab-scale preparations. The curcumin encapsulated nanoparticles were freeze-dried using sucrose (5 %, w/v) as a cryoprotectant. The freeze-dried nanoparticles were subjected to 6-month stability study as per the International Conference on Harmonisation guideline at room temperature and refrigerated storage conditions. Intermediate sampling was done (monthly), and the nanoparticles were thoroughly characterised for particle size, entrapment efficiency, surface morphology and crystallinity, which were compared to fresh preparations. The curcumin encapsulated PLGA nanoparticles were found to be stable at refrigerated as well as room temperature storage test conditions indicated by their particle characteristics. X-ray diffraction results confirm amorphous nature of curcumin on nano-encapsulation that stays intact after freeze drying and 6-month stability testing. Together these data offer possibility of producing large quantities of polymer nanoparticles that are suitable for room as well as refrigerated storage conditions opening up possibilities to conduct repeated dosings in a chronic setting or regulatory toxicology studies of such nanomedicines.

Entities:  

Year:  2013        PMID: 25788136     DOI: 10.1007/s13346-013-0150-2

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  16 in total

Review 1.  Small-scale systems for in vivo drug delivery.

Authors:  David A LaVan; Terry McGuire; Robert Langer
Journal:  Nat Biotechnol       Date:  2003-10       Impact factor: 54.908

2.  Tissue localization of nanoparticles is altered due to hypoxia resulting in poor efficacy of curcumin nanoparticles in pulmonary hypertension.

Authors:  Venkat Ratnam Devadasu; Roger M Wadsworth; M N V Ravi Kumar
Journal:  Eur J Pharm Biopharm       Date:  2011-12-30       Impact factor: 5.571

3.  Can efficient delivery systems leverage benefits of antioxidants leading to potential medicines?

Authors:  M N V Ravi Kumar
Journal:  Drug Discov Today       Date:  2012-02-04       Impact factor: 7.851

4.  The dark side of curcumin.

Authors:  Estefanía Burgos-Morón; José Manuel Calderón-Montaño; Javier Salvador; Antonio Robles; Miguel López-Lázaro
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

Review 5.  Can controversial nanotechnology promise drug delivery?

Authors:  Venkat Ratnam Devadasu; Vivekanand Bhardwaj; M N V Ravi Kumar
Journal:  Chem Rev       Date:  2012-12-31       Impact factor: 60.622

6.  Protective effects of nanoparticulate coenzyme Q10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications.

Authors:  Venkat Ratnam Devadasu; Roger M Wadsworth; M N V Ravi Kumar
Journal:  Drug Deliv Transl Res       Date:  2011-12       Impact factor: 4.617

7.  Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations.

Authors:  Yong Soon Chun; Savita Bisht; Venugopal Chenna; Dipankar Pramanik; Takahiro Yoshida; Seung-Mo Hong; Roeland F de Wilde; Zhe Zhang; David L Huso; Ming Zhao; Michelle A Rudek; Vered Stearns; Anirban Maitra; Saraswati Sukumar
Journal:  Carcinogenesis       Date:  2012-07-25       Impact factor: 4.944

8.  Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance.

Authors:  P Muthenna; P Suryanarayana; Shravan K Gunda; J Mark Petrash; G Bhanuprakash Reddy
Journal:  FEBS Lett       Date:  2009-10-20       Impact factor: 4.124

Review 9.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

10.  Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

Authors:  Yvonne G Lin; Ajaikumar B Kunnumakkara; Asha Nair; William M Merritt; Liz Y Han; Guillermo N Armaiz-Pena; Aparna A Kamat; Whitney A Spannuth; David M Gershenson; Susan K Lutgendorf; Bharat B Aggarwal; Anil K Sood
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

View more
  4 in total

1.  Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus.

Authors:  Raghu Ganugula; Meenakshi Arora; Patcharawalai Jaisamut; Ruedeekorn Wiwattanapatapee; Heather G Jørgensen; Vinod P Venkatpurwar; Beiyan Zhou; Aline Rodrigues Hoffmann; Rita Basu; Shaodong Guo; Naga Venkata Ravi Kumar Majeti
Journal:  Br J Pharmacol       Date:  2017-05-30       Impact factor: 8.739

2.  Next-Generation Noncompetitive Nanosystems Based on Gambogic Acid: In silico Identification of Transferrin Receptor Binding Sites, Regulatory Shelf Stability, and Their Preliminary Safety in Healthy Rodents.

Authors:  M Arora; R Ganugula; N Kumar; G Kaur; J-P Pellois; P Garg; M N V Ravi Kumar
Journal:  ACS Appl Bio Mater       Date:  2019-07-04

Review 3.  Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer.

Authors:  Sheikh Tasnim Jahan; Sams M A Sadat; Matthew Walliser; Azita Haddadi
Journal:  J Drug Deliv       Date:  2017-12-31

4.  Oral Nano-Curcumin in a Model of Chronic Gulf War Illness Alleviates Brain Dysfunction with Modulation of Oxidative Stress, Mitochondrial Function, Neuroinflammation, Neurogenesis, and Gene Expression.

Authors:  Sahithi Attaluri; Meenakshi Arora; Leelavathi N Madhu; Maheedhar Kodali; Bing Shuai; Laila Melissari; Raghavendra Upadhya; Xiaolan Rao; Adrian Bates; Eeshika Mitra; Keyhan R Ghahfarouki; M N V Ravikumar; Ashok K Shetty
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.